Linked e-resources
Details
Table of Contents
Part-1: General. History of Neuroendocrine Neoplasia
Epidemiology of neuroendocrine neoplasms. Part-2: Diagnosis. New concepts in patholog
Molecular Biology of Neuroendocrine Tumors
Circulating biochemical markers of gastro-entero-pancreatic (GEP) neuroendocrine neoplasms (NENs)
Advances in diagnostic imaging. Part-3: New Approaches for Treatment. Treatment of NET related symptoms
New Surgical Strategies
New approaches in medical therapies
Loco-regional Therapies of NEN
Radioreceptor therapy
NETs of the lung
Part-4: Treatment of NETs From Different Organ Origin. Gastric Neuroendocrine Tumors
Treatment of Pancreatic Neurendocrine Tumors
Treatment of intestinal NETs (including appendix)
Treatment of NETs from rare origin
Neuroendocrine Neoplasms with Peculiar Biology and Features: MEN1, MEN2A, MEN2B, MEN4, VHL, NF1. Part-5: NETs with Peculiar Biology and Feature. Mixed Neuroendocrine and Non-Neuroendocrine Neoplasms (Mi NEN)
Merkel Cell Carcinoma
Therapy in poorly differentiated neuroendocrine neoplasms (NEN G3)
Conclusion:NENs management today looking at the future.
Epidemiology of neuroendocrine neoplasms. Part-2: Diagnosis. New concepts in patholog
Molecular Biology of Neuroendocrine Tumors
Circulating biochemical markers of gastro-entero-pancreatic (GEP) neuroendocrine neoplasms (NENs)
Advances in diagnostic imaging. Part-3: New Approaches for Treatment. Treatment of NET related symptoms
New Surgical Strategies
New approaches in medical therapies
Loco-regional Therapies of NEN
Radioreceptor therapy
NETs of the lung
Part-4: Treatment of NETs From Different Organ Origin. Gastric Neuroendocrine Tumors
Treatment of Pancreatic Neurendocrine Tumors
Treatment of intestinal NETs (including appendix)
Treatment of NETs from rare origin
Neuroendocrine Neoplasms with Peculiar Biology and Features: MEN1, MEN2A, MEN2B, MEN4, VHL, NF1. Part-5: NETs with Peculiar Biology and Feature. Mixed Neuroendocrine and Non-Neuroendocrine Neoplasms (Mi NEN)
Merkel Cell Carcinoma
Therapy in poorly differentiated neuroendocrine neoplasms (NEN G3)
Conclusion:NENs management today looking at the future.